Press Releases Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
13.58 ^USD	-3.00%		+0.59%	+18.29%

May. 24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
May. 22	Alvotech Narrows Q1 Loss as Revenue Increases; Shares Head Higher Premarket	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Teva and Alvotech Announce SIMLANDI Injection Now Available in the U.S.	May. 22	AQ
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update	May. 21	GL
Alvotech : and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK	May. 21	PU
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK	May. 21	GL
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	May. 20	AQ
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.	May. 20	GL
Alvotech S.A. Annual General Meeting to be held June 7, 2024	May. 15	GL
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)	May. 13	AQ
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)	May. 13	GL
Alvotech : General Meeting Alvotech - Convening Notice (AGM 2024)	May. 06	PU
Alvotech Announces Positive Topline Results From Confirmatory Clinical Study For Its Proposed Golimumab Biosimilar	May. 02	AQ
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024	May. 02	GL
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira	May. 01	AQ
Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Biosimilar To Stelara® Approved By FDA	May. 01	AQ
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	Apr. 30	GL
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar	Apr. 26	AQ
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi	Apr. 25	AQ
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)	Apr. 24	GL
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira	Apr. 22	AQ
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)	Apr. 19	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Alvotech

Equities

ALVO

LU2458332611

Press Releases

Filters